Genus plc Stock
There is an upward development for Genus plc compared to yesterday, with an increase of €0.40 (1.120%).
Pros and Cons of Genus plc in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 1.120% | 2.874% | 11.875% | 68.868% | 21.769% | 9.146% | -40.333% |
| Iovance Biotherapeutics Inc. | 3.210% | 44.357% | 43.418% | -39.647% | 34.802% | -51.859% | -90.116% |
| United Therapeutics | 0.650% | -1.326% | 1.311% | 17.280% | -5.968% | 69.679% | 180.979% |
| Neurocrine Bioscience | 1.740% | 3.106% | -3.472% | -2.285% | -8.890% | 14.486% | 22.440% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat